Summit Trail Advisors LLC Sells 6,411 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Summit Trail Advisors LLC decreased its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 1.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 358,652 shares of the company’s stock after selling 6,411 shares during the period. Summit Trail Advisors LLC owned 0.17% of Hims & Hers Health worth $6,606,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Alpha DNA Investment Management LLC bought a new position in Hims & Hers Health in the 3rd quarter valued at $552,000. Charles Schwab Investment Management Inc. lifted its stake in shares of Hims & Hers Health by 15.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,667,422 shares of the company’s stock valued at $30,714,000 after acquiring an additional 218,566 shares during the period. Massachusetts Financial Services Co. MA bought a new position in Hims & Hers Health in the third quarter valued at about $2,395,000. Intech Investment Management LLC acquired a new stake in Hims & Hers Health in the third quarter worth about $1,064,000. Finally, Quest Partners LLC raised its holdings in Hims & Hers Health by 22.6% during the 3rd quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock worth $81,000 after purchasing an additional 807 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Price Performance

NYSE:HIMS opened at $25.33 on Friday. The business’s 50-day simple moving average is $20.55 and its 200-day simple moving average is $19.26. Hims & Hers Health, Inc. has a fifty-two week low of $8.02 and a fifty-two week high of $30.44. The stock has a market capitalization of $5.53 billion, a PE ratio of 57.57 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.06 by $0.26. The firm had revenue of $401.56 million for the quarter, compared to the consensus estimate of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business’s quarterly revenue was up 77.1% on a year-over-year basis. During the same period last year, the company posted ($0.04) EPS. On average, research analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, CEO Andrew Dudum sold 188,888 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $14.56, for a total transaction of $2,750,209.28. Following the completion of the transaction, the chief executive officer now owns 33,502 shares of the company’s stock, valued at $487,789.12. This represents a 84.94 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Oluyemi Okupe sold 269,739 shares of Hims & Hers Health stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $20.31, for a total transaction of $5,478,399.09. Following the completion of the sale, the chief financial officer now owns 145,763 shares in the company, valued at $2,960,446.53. This trade represents a 64.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,056,183 shares of company stock valued at $21,501,682. 17.71% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

HIMS has been the topic of several recent research reports. Piper Sandler reaffirmed a “neutral” rating and issued a $21.00 target price (up previously from $18.00) on shares of Hims & Hers Health in a research note on Tuesday, November 5th. Bank of America cut shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and reduced their price objective for the company from $32.00 to $18.00 in a research note on Thursday, November 14th. Deutsche Bank Aktiengesellschaft lifted their target price on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a report on Wednesday, November 6th. Canaccord Genuity Group increased their price target on Hims & Hers Health from $24.00 to $28.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. Finally, Imperial Capital cut Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research note on Friday, August 9th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and seven have given a buy rating to the stock. According to MarketBeat, Hims & Hers Health has an average rating of “Hold” and a consensus price target of $20.71.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.